CRISPR Therapeutics AG (CRSP) Free Cash Flow (2015 - 2026)
CRISPR Therapeutics AG (CRSP) reported Free Cash Flow of -$109.4 million for Q1 2026, down 102.02% on a YoY basis from $5.4 billion in Q1 2025, and down 17.55% sequentially from -$93.1 million in Q4 2025.
CRISPR Therapeutics AG (CRSP) Free Cash Flow (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 12 years of Free Cash Flow data on file, last reported at -$109.4 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 102.02% year-over-year to -$109.4 million; the trailing twelve-month figure through Mar 2026 stood at -$401.2 million (down 31.06% YoY), and the FY2025 full-year result was -$345.9 million, down 142.03% from the prior year.
- Free Cash Flow slipped to -$109.4 million in Q1 2026, from -$93.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $109.0 million in Q1 2024 to a low of -$161.0 million in Q2 2022.
- A 5-year average of -$79.8 million and a median of -$96.0 million in 2023 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 1799.49% in 2024, while the deepest fall reached 170.67% in 2024.
- Tracing CRSP's Free Cash Flow over 5 years: stood at -$110.5 million in 2022, then gained by 13.11% to -$96.0 million in 2023, then soared by 49.46% to -$48.5 million in 2024, then slumped by 91.75% to -$93.1 million in 2025, then slipped by 17.55% to -$109.4 million in 2026.
- Business Quant data shows CRSP's Free Cash Flow at -$109.4 million in Q1 2026, -$93.1 million in Q4 2025, and -$84.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | -109.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -109.40 Mn |
| Mar 31, 2026 | -109.40 Mn |
| Dec 31, 2025 | -93.07 Mn |
| Dec 31, 2025 | -93.07 Mn |
| Sep 30, 2025 | -84.71 Mn |
| Sep 30, 2025 | -84.71 Mn |
| Jun 30, 2025 | -114.00 Mn |
| Jun 30, 2025 | -114.00 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Dec 31, 2024 | -48.54 Mn |
| Dec 31, 2024 | -48.54 Mn |
| Sep 30, 2024 | -107.13 Mn |
| Sep 30, 2024 | -107.13 Mn |
| Jun 30, 2024 | -96.29 Mn |
| Jun 30, 2024 | -96.29 Mn |
| Mar 31, 2024 | 109.03 Mn |
| Mar 31, 2024 | 109.03 Mn |
| Dec 31, 2023 | -96.05 Mn |
| Dec 31, 2023 | -96.05 Mn |